Across TCGA pan-cancer cohorts, DPY19L1P1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated DPY19L1P1 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher DPY19L1P1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DPY19L1P1 expression acts as an unfavorable survival marker.
ESCA and SKCM are the cancer types where DPY19L1P1 Mutation most reproducibly stratifies survival.